Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2018-03-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - THE GROUP'S DRUG "BUTYLPHTHALIDE" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the U.S. FDA granting orphan-drug designation to one of its drugs. It is an announcement about a regulatory milestone related to drug development and does not contain financial data, management discussion, or detailed report content. The document is relatively short (3425 characters) and serves as a public announcement rather than a detailed report or filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory certification or officer attestation. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2018-03-11 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve final results for the year ended 31 December 2017 and to consider a final dividend. It does not contain any financial data or detailed report content but merely announces the upcoming board meeting and its agenda. The length is only 1309 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such short announcements about board meetings and report approvals are best classified as Regulatory Filings (RNS) since it is a general regulatory announcement and does not fit other specific categories like Annual Report or Earnings Release. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2018-03-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 28/02/2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's share capital structure during a specific month. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements, which fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories.
2018-03-02 English
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of a new product. It is a short announcement (3128 characters) that informs the public about regulatory approval and the significance of the product launch. There are no financial statements, detailed financial data, or comprehensive report content. The document does not present an annual or interim report, earnings release, or any detailed investor presentation. It is not a regulatory filing in the sense of compliance or certification, nor is it a voting result or management change announcement. Given the nature and length, this fits best as a Regulatory Filings (RNS) type, which is a fallback category for miscellaneous announcements that do not fit other specific categories.
2018-02-11 English
VOLUNTARY ANNOUNCEMENT-THE GROUP'S GASTRIC CANCER DRUG "DP303c" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the Board of Directors of CSPC Pharmaceutical Group Limited regarding the orphan-drug designation granted by the U.S. FDA to their gastric cancer drug DP303c. It is a short announcement (3228 characters) that provides specific news about a regulatory milestone for a drug, not a financial report or detailed management discussion. There is no financial data, no mention of annual or quarterly results, no voting results, no board changes, no legal proceedings, or other report types. The document is an announcement of a significant event related to the company's product development and regulatory status. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-02-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2018
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/01/2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and securities movements rather than financial performance, management commentary, or regulatory certifications. It is a regulatory filing reporting monthly share capital movements, not a full financial report or announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2018-02-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.